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Abstract
Background: Up to 90 % of people with scleroderma have gastrointestinal (GI) problems such as constipation,
bloating, diarrhea, and malabsorption. These problems significantly impair quality of life. Our objective was to
determine the risk factors for gastrointestinal issues in people with scleroderma.
Methods: We conducted a systematic review of observational studies that report GI problems in patients with
scleroderma along with the associated risk factors. We were interested in any GI problem and any risk factor as
long as the study included patients diagnosed with scleroderma according to the 1980 or 2013 American College
of Rheumatology guideline. We searched the following databases: CINAHL, EMBASE, LILACS, MEDLINE, and Web of
Science for relevant articles from June 1884 to May 2014. Two authors independently screened citations and full
text articles and extracted data. Discrepancies were resolved by consensus or by consulting a third author.
Methodological quality of included studies was assessed using the Newcastle-Ottawa Scale.
Results: After removing duplicates, 645 unique citations were identified. A total of three studies, three cross-
sectional (n = 64, n = 42, n = 606), were included in this systematic review. Collectively, these three studies
explored Helicobacter pylori and smoking status as risk factors. We found conflicting evidence on the role of H.
pylori with two studies showing opposite yet statistically significant results. One moderate quality study showed
smoking as a risk factor. Key limitations include the small sample sizes of two studies and poor study designs to
draw causal links.
Conclusions: There is insufficient evidence to describe the risk factors for GI problems in patients with
scleroderma. Longitudinal observational studies are warranted in patients with scleroderma.
Systematic review registration: PROSPERO CRD42014010707
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Background
Scleroderma, otherwise known as systemic sclerosis, is a
disease manifested by collagen overproduction affecting
various organs including the gastrointestinal (GI) tract
[1]. Patients with scleroderma commonly present with
inflammation and fibrosis of the skin, vascular abnor-
malities, organ damage, and autoantibody production
[2]. Diagnosis is made when these signs and correspond-
ing symptoms are present [3]. Scleroderma is a debilitat-
ing disease that is estimated to affect approximately
16,000 Canadians—with four to five times more females
than males [1]. The prevalence of the disease is higher
among people of African origin and varies across coun-
tries, appearing more in North America and Australia
than in Europe and Japan [4]. Scleroderma is associated
with debilitating morbidity such as reduction in mobility
and depression [5]. Patients with this disorder have a
30.8 % mortality rate, although this number can vary de-
pending on gender and which visceral organs are in-
volved [6]. Currently, there are no effective treatments
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to combat scleroderma, partly because its pathogenesis
remains unclear [7]. Consequently, much attention has
shifted towards predicting the complications of sclero-
derma and managing them appropriately [8]. The under-
lying rationale is that it is easier to manage the disease
before these complications arise [8].
In around 90 % of all patients with scleroderma, the
GI tract is involved. This contributes considerably to im-
pairment in quality of life [9–11]. Malabsorption, gastro-
esophageal reflux, nausea, vomiting, diarrhea, and
constipation are some of the GI complications that can
occur [9]. Although environmental risk factors are
clearly linked to increased risk of developing sclero-
derma [12], it is unclear whether the GI involvement
secondary to scleroderma is influenced by these environ-
mental factors [12]. This study reviews the association
between GI involvement and environmental and other
exposures in patients with scleroderma. These findings
will help patients with scleroderma and healthcare pro-
fessionals in preventing GI morbidity. In Canada, the
average annual economic burden of scleroderma is esti-
mated to be $18,453 per patient [13]. Knowing that the
cost of care for patients with scleroderma increases with
more organ involvement, the findings from this study
can inform policy developers to identify ways to curb
healthcare costs [13]. The objective of this systematic re-
view was to determine the factors associated with devel-
opment of GI problems in patients with scleroderma.
Methods
Criteria for inclusion of studies
Design and time frame
Observational studies from June 1884 to May 2014 were
considered in this review. June 1884 was chosen because it
is the earliest entry of scleroderma in available databases.
Exposure
The exposures of interest were silica, silicone implantation
and rupture, antacid, solvents, epoxy resins, welding fumes,
anorexigens, pentazocine, bromocriptine, L-tryptophan,
pesticides, constant hand/arm vibration, alcohol, intestinal
microbiota, and food along with any other reported risk
factors [14–19].
Participants
The population of interest was patients with a formal diag-
nosis of systemic sclerosis according to the 1980 and 2013
American College of Rheumatology guidelines [20, 21].
Outcome
Outcomes of interest included any reported GI problems
such as nausea, vomiting, and diarrhea.
Search methods for identification of studies
Search strategy
The lead author (BYH) with the help of a hospital librar-
ian (LC) developed the search strategy. We designed a
comprehensive and exhaustive search strategy of five
electronic databases to identify observational studies that
reported on risk factors for GI problems in scleroderma.
Our search strategy for MEDLINE via Ovid is reported
in Table 1.
Databases searched
Cumulative Index to Nursing and Allied Health Litera-
ture (CINAHL), Excerpta Medica database (EMBASE),
Latin American and Caribbean Health Sciences Litera-
ture (LILACS), Medical Literature Analysis and Retrieval
System Online (MEDLINE), and Web of Science were
searched to identify relevant citations for this systematic
review.
Other sources searched
We manually checked the reference lists of studies identi-
fied in an attempt to identify additional publications. Con-
ference websites were not separately searched because
EMBASE catalogues abstracts from several notable
rheumatology conferences. A practicing rheumatologist
and also an author of this review (ML) was queried to
identify additional studies. We searched the Scleroderma
Society of Canada, the Scleroderma Foundation, and the
Scleroderma Research Foundation websites.
Study screening, selection, and assessment of
methodological quality
Two authors (BYH and RJ), working independently,
reviewed all citations and abstracts resulting from the
search strategy to identify eligible papers. The full text of
eligible articles were obtained and assessed independ-
ently using a pre-designed eligibility form based on the
inclusion criteria. Eligible studies were included in the
review. Disagreements were resolved by discussion or by
seeking the opinion of a third party (LT/ML). The two
authors (BYH and RJ) independently assessed the meth-
odological quality of included studies using the
Newcastle-Ottawa Scale and extracted data using a pre-
established data extraction form [22].
Data analysis
We planned to pool the results using the DerSimmonian
and Laird random effects method if there was a measure of
relative risk (risk ratio, odds ratio, hazard ratio) and preci-
sion (95 % confidence intervals, standard error, variance)
and if there was sufficient clinical and statistical homogen-
eity [23], and present the results as an odds ratios with
95 % confidence interval and p values. Between-study het-
erogeneity was also to be tested using Cochran’s Q and the
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I2 statistic. However, given the considerable clinical and de-
sign heterogeneity in the included studies, we adopted a
narrative approach to summarize our findings.
Results
Results of search
Our electronic literature search identified a total of 645
unique citations after duplicates were removed. One
study was identified by searching the reference lists of
included studies, but was excluded from this review.
Title and abstract screening identified 235 articles that
were potentially eligible for inclusion. During the full
text screening, 232 citations were removed resulting in a
total of three studies being included [24–26]. Figure 1
provides a flow diagram of the study selection process
and the reasons for exclusion.
Overview of study characteristics and summary of study
findings
There were three studies included in this systematic review,
conducted in Japan, Canada, and Croatia in 2008, 2011,
and 2013, respectively [24–26]. The number of enrolled
patients ranged from 42 to 606 with the total of 712 pa-
tients included in this systematic review [24–26]. All three
citations were cross-sectional studies [24–26]. Although all
three studies examined GI problems as the outcome of
interest, only one used endoscopic examination to diagnose
reflux esophagitis [24], while the other two relied on self-
reported severity of GI problems. Two studies examined
Helicobacter pylori as a risk factor for GI problems in
patients with scleroderma but gave contrasting results [24,
26]. The three included studies are summarised in Table 3.
Yamaguchi et al. [24]
The study by Yamaguchi et al. was a cross-sectional
study that examined whether or not the presence of H.
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pylori infection was associated with reflux esophagitis in
patients with scleroderma. Of the 138 patients with
scleroderma, 74 were excluded because they were taking
medications for their GI issues or had laparotomy. Of
the remaining 64 patients (mean age = 60.7 years, %
female 81.3, % diffuse disease 17), 37 were H. pylori
positive. Without adjusting for covariates, it was found
that being H. pylori positive is protective against reflux
esophagitis in patients with scleroderma (OR = 0.16,
95 % CI = 0.05–0.47).
Hudson et al. [25]
The study by Hudson et al. was also a cross-sectional
study, which examined whether smoking (never, past, or
current) was associated with GI problems in patients with
Fig. 1 Flow diagram of study selection
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Table 3 Summary of included studies
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Table 3 Summary of included studies (Continued)
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scleroderma. It examined the presence of 14 different GI
problems and the severity of GI symptoms. Six hundred
and six patients (mean age = 55.3 years, % female 87, %
diffuse disease 36) were included in the analysis. Adjusted
for covariates (age, gender, ethnicity, disease duration, dif-
fuse disease), the regression model showed that only the
number of GI symptoms and poor appetite showed statis-
tical significant worsening with smoking.
Radic et al. [26]
The study by Radic et al. was another cross-sectional
study that examined whether or not the presence of H.
pylori infection was associated with self-reported GI
problems in patients with scleroderma. Of the 42 pa-
tients (mean age = 54.3 years, % female 90.5, % diffuse
disease 95.3), 26 were H. pylori positive. An adjusted
analysis revealed that being H. pylori positive is corre-
lated with high prevalence of GI issues.
Methodological quality of included studies
Methodological quality of included studies was assessed
using the Newcastle-Ottawa Scale and graded according to
the guidelines [22]. Being that all three studies were cross-
sectional, two criteria regarding follow-up in the
Newcastle-Ottawa Scale did not apply. Thus, of the possible
6 points, Yamaguchi et al. scored 4, Radic et al. scored 5,
and Hudson et al. scored 6 points. Overall, the quality of in-
cluded studies were generally low (see Table 2).
Discussion
Summary of main findings
A total of three cross-sectional studies generally of low
quality were included in this systematic review (Table 3).
Two studies explored H. pylori infection as a risk factor
for GI problems in patients with scleroderma but
showed opposing results. Although Yamaguchi et al. [24]
had a slightly bigger sample size, only Radic et al. [26]
controlled for confounding variables in the analysis. The
difference between these two studies may also be attrib-
utable to the difference in the patient demographics and
outcome adjudication. Only 17 % of the patients had dif-
fuse scleroderma in Yamaguchi et al.’s study, while 95 %
had diffuse scleroderma in Radic et al.’s study [26]. Fur-
thermore, Yamaguchi et al. [24] employed endoscopic
examination to diagnose reflux esophagitis, while Radic
et al. [26] used patient-reported GI problems. Hudson et
al.’s study examines the effect of smoking on GI prob-
lems in patients with scleroderma and showed that
higher proportion of patients with scleroderma who
smoke had GI problems [25]. Yamaguchi et al., Hudson
et al., and Radic et al. [24–26] looked at reflux esopha-
gitis, poor appetite, and GI symptom severity as the out-
come, respectively. None of the papers reviewed
discussed other environmental exposures such as silica
and epoxy.
Limitations
There are limitations to be noted in our systematic
review. First, while our search did not include the
gray literature, we undertook a thorough and rigorous
search of CINAHL, EMBASE, GI, LILACS, and MED-
LINE. Second, the extent of available data with
regards to covariates was limited and the length of
follow-up was often not specified, which may not be
adequate for the observation of GI problems in pa-
tients with scleroderma. Third, all three studies are
cross-sectional, which are not useful in determining
predictors of outcome. These deficiencies highlight
the need for further research to address the current
knowledge gap exploring the risk factors associated
with GI problems in patients with scleroderma.
Implications for practice
There is not enough evidence to inform clinical practice.
This paper included three studies that report H. pylori
infection (two studies) and smoking (one study) as po-
tential risk factors for GI problems in patients with
scleroderma. Given that the evidence is sparse and gen-
erally of low quality and that the two included studies
on H. pylori contradict each other. It is unclear how to
incorporate these findings into clinical practice. Smok-
ing, however, seems to be associated with a wide range
of GI problems.
Implications for research
In the field of scleroderma, longitudinal observational
studies are warranted to investigate the risk factors
for GI problems. For rare exposures like silica and
pesticides, case-control designs may be more appro-
priate. A wealth of useful information can also be ob-
tained from well-kept scleroderma registries. The
studies should include patients with scleroderma
followed up prior to and after the development of GI
problems. Data on all potential risk factors including
H. pylori infection, smoking, exposure to environmen-
tal toxins, and others should be collected. All possible
GI problems should be explored, including data on
morbidity and mortality.
Conclusions
There is a lack of evidence to conclusively suggest or re-
fute whether H. pylori infection or smoking is a defini-
tive risk factor for developing GI problems in patients
with scleroderma.
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